Epigenetic Reprogramming: The First Human De-Aging Trial

A $720 Million Lesson, and a Second Act

In January 2026, the FDA cleared the first human clinical trial of a partial epigenetic reprogramming therapy. The treatment, called ER-100, is an eye injection developed by Life Biosciences, a company co-founded by Harvard geneticist David Sinclair. Three participants with severe vision loss will receive a single injection of a modified viral vector carrying three genes that, in mice, reversed blindness.¹

The longevity internet lost its mind. "De-aging is here." "They're literally reversing aging in humans." "Sinclair was right all along." Within 48 hours, the story had been shared millions of times, filtered through a social media ecosystem that has learned to strip nuance from science the way a centrifuge strips plasma from blood.

I want to be careful here, because the underlying science is genuinely compelling. The preclinical data is some of the strongest I've reviewed in this newsletter. But the man behind it has a history of overpromising that should give any careful reader pause. And the distance between injecting three genes into a mouse's eye and reversing human aging is measured not in years, but in the graveyard of failed clinical translations that came before.

So let's do what we always do. Read the studies. Check the footnotes. Follow the money.

Your Cells Have a Backup Drive. Aging Corrupts It.

The central idea behind epigenetic reprogramming is elegant. Every cell in your body contains the same DNA, but different cells read different parts of it. A skin cell reads skin genes. A neuron reads neuron genes. The system that controls which genes are active and which are silent is called the epigenome, a layer of chemical marks, primarily methyl groups, attached to DNA and its associated proteins.²

Sinclair's "Information Theory of Aging," published in Cell in January 2023, proposes that aging is not primarily caused by mutations in your DNA. Instead, it's caused by the gradual loss of epigenetic information. Think of it this way: your genome is the hardware, but the epigenome is the software. Over time, the software accumulates errors. Cells lose track of which genes should be on and which should be off. A liver cell starts expressing genes meant for a kidney cell. The result is the functional decline we call aging.³

The radical claim is that this process is reversible. If aging is an information problem, and if cells retain a "backup copy" of their youthful epigenetic program, then theoretically you could restore that backup. The question was always: how?

The answer came from Shinya Yamanaka's Nobel Prize-winning discovery in 2006. He identified four transcription factors, Oct4, Sox2, Klf4, and c-Myc, collectively known as OSKM, that could reprogram any adult cell back into a stem cell. The problem was that full reprogramming erases a cell's identity entirely. A reprogrammed skin cell stops being a skin cell. In living animals, that leads to teratomas, uncontrolled growths of disorganized tissue.⁴

Sinclair's insight was to use only three of the four factors, OSK, and to express them briefly. Drop c-Myc, which is a known cancer-promoting gene. Keep the exposure transient. The cells rejuvenate, their epigenetic marks reset toward youth, but they retain their identity. A retinal cell stays a retinal cell. It just becomes a younger one.⁵

Blind Mice That Could See Again. Old Mice That Lived Twice as Long.

The preclinical evidence for partial epigenetic reprogramming is, I'll say it plainly, remarkable. Three studies in particular form the foundation of the human trial that is now underway.

There is also a fourth study worth mentioning. In July 2023, Sinclair's lab published a paper in Aging showing that small-molecule chemical cocktails, not gene therapy, could reverse human cell epigenetic age by more than three years in just four days.⁹ If validated, this could eventually lead to oral medications rather than viral injections. But the compounds used, including valproic acid, CHIR-99021, and tranylcypromine, have known toxicity concerns that Sinclair's critics have highlighted.¹⁰

One Injection, Eight Weeks of Doxycycline, and a Lot of Hope

On January 28, 2026, the FDA cleared Life Biosciences' Investigational New Drug (IND) application for ER-100, making it the first partial epigenetic reprogramming therapy ever approved for human testing.¹ The trial is registered as NCT07290244.

Here is what the trial actually involves. Adults aged 40 to 85 with either open-angle glaucoma or NAION, both conditions involving death of retinal ganglion cells, receive a single injection of ER-100 into one eye. The treatment delivers a modified AAV vector carrying OSK genes. Patients then take oral doxycycline for eight weeks, which activates the reprogramming genes. After eight weeks, the doxycycline stops, and the genes switch off.¹

The initial cohort is three participants. After a safety review committee evaluates the first three, enrollment may expand to six. The primary endpoints are safety and tolerability, not efficacy. Secondary endpoints include visual function assessments and retinal health markers. Exploratory endpoints include measures of epigenetic age in accessible cells.¹

This is important to understand: the FDA did not approve a de-aging therapy. They approved a safety test of a gene therapy for eye disease. The trial is designed to answer one question: is this safe enough to keep studying? Results are expected by late 2026 or early 2027.

The choice of the eye was strategic. It is anatomically isolated, limiting systemic exposure. It has well-established clinical endpoints. And it builds directly on the mouse and primate data that showed vision restoration. If ER-100 causes problems, the eye is about the safest place to discover that.

Resveratrol, NMN, and the Pattern of Overpromising

I cannot review David Sinclair's latest work without reviewing his history. And his history is complicated.

In 2003, Sinclair published papers in Nature and Science claiming that resveratrol, a compound found in red wine, activated the SIRT1 longevity gene. The media coverage was enormous. Red wine became a health food overnight. Sinclair co-founded a company, Sirtris Pharmaceuticals, to develop sirtuin-activating drugs. In 2008, GlaxoSmithKline acquired Sirtris for $720 million.⁸

Then it fell apart. Independent laboratories at Amgen and Pfizer demonstrated that the fluorescent assay Sinclair's team had used was non-specific. Resveratrol didn't actually activate sirtuins the way the original studies suggested. GSK's lead clinical compound, SRT501, failed Phase 2 trials with severe side effects including nausea, vomiting, and kidney damage. By 2013, GSK had shut down Sirtris entirely, having spent hundreds of millions on a target that didn't work as advertised.^8,11

More recently, Sinclair championed NMN (nicotinamide mononucleotide) as an NAD+ precursor supplement that could slow aging. The Corneum covered the NAD+ supplement space in Issue #010. What makes the NMN story unusual is that in 2022, the FDA reclassified NMN from a dietary supplement to an investigational new drug, effectively banning its sale. Critics, including prominent NAD+ researcher Charles Brenner at the University of Delaware, alleged that this reclassification was influenced by pharmaceutical interests connected to Sinclair, who stood to benefit from NMN becoming a prescription product.^10,12

In 2024, following what was described as "controversial claims made by an affiliated company," Sinclair resigned as president of the Academy for Health and Lifespan Research. The specific details of the controversy have not been made public.¹³

None of this means the epigenetic reprogramming research is wrong. Good scientists can have complicated histories. But the pattern, bold claims, media saturation, commercial entanglement, followed by complications, is relevant context when evaluating new claims from the same source. As Brenner has noted: "Independent labs have had trouble replicating Dr. Sinclair's results published as early as 2003."¹⁰

Five Companies, Billions of Dollars, and No Human Efficacy Data

Life Biosciences is not alone. A constellation of well-funded startups is racing to bring epigenetic reprogramming to the clinic, and the investment numbers are staggering.

Retro Biosciences, funded with $180 million from OpenAI CEO Sam Altman, initiated its own first-in-human partial reprogramming trial in 2025, slightly ahead of Life Bio. Early safety data reportedly showed no dose-limiting toxicities at the lowest dose levels tested. Retro is now raising a Series A at a reported $5 billion valuation with a $1 billion fundraising target.¹⁴

NewLimit, valued at $1.62 billion after a $130 million Series B plus an additional $45 million from Eli Lilly, is pursuing epigenetic reprogramming of the immune system and liver. The company is in IND-enabling studies and plans to enter human trials within the next few years.¹⁵

Turn Biotechnologies is developing mRNA-based transient reprogramming for skin rejuvenation. Their preclinical work showed increased collagen I and VII production and decreased senescence markers in human skin fibroblasts. They plan to initiate human skin trials in 2026.¹⁶

Altos Labs, backed by some of the wealthiest people in technology, is pursuing partial reprogramming across multiple tissue types. They have early human testing underway but have not published results.¹⁷

The cellular reprogramming therapy market was valued at $4.1 billion in 2025 and is projected to reach $23.8 billion by 2034, a compound annual growth rate of 19.5%.¹⁸ There is an enormous amount of money chasing this science, which creates both opportunities and incentives for premature claims.

What none of these companies have is human efficacy data. Not one of them has published evidence that partial epigenetic reprogramming improves any clinical outcome in any human patient. Every company is still in the safety-testing phase. The field is pre-proof.

Beautiful Science, Complicated Messenger, No Human Proof Yet